Sarepta Therapeutics, Inc.

SRPT

$20.34

Name : Sarepta Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,135,492,096.00

EPSttm : -7.13

Sarepta Therapeutics, Inc.

$20.34

1.85%

$0.37

SRPT — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

23.02

Margin Of Safety %

Put/Call OI Ratio

0.81

EPS Next Q Diff

5.03

EPS Last/This Y

11.3

EPS This/Next Y

-1.39

Price

19.94

Target Price

22.33

Analyst Recom

2.69

Performance Q

-10.53

Upside

-649.4%

Beta

0.26

Ticker: SRPT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	SRPT	16.31	0.94	0.63	112088
2026-03-03	SRPT	15.88	0.94	1.93	113552
2026-03-04	SRPT	16.13	0.95	0.72	114971
2026-03-05	SRPT	16.23	0.94	0.60	115501
2026-03-06	SRPT	16.72	0.94	0.13	115488
2026-03-09	SRPT	17.64	0.90	0.29	118018
2026-03-10	SRPT	17.66	0.89	0.15	119925
2026-03-11	SRPT	17.58	0.86	0.57	122179
2026-03-12	SRPT	17.04	0.87	1.08	123274
2026-03-13	SRPT	17.04	0.87	1.09	123274
2026-03-17	SRPT	16.85	0.88	0.52	122564
2026-03-18	SRPT	17.17	0.88	0.47	123418
2026-03-19	SRPT	16.66	0.87	0.66	123924
2026-03-20	SRPT	16.7	0.86	0.43	124924
2026-03-23	SRPT	17.7	0.89	0.90	112327
2026-03-24	SRPT	17.62	0.89	0.42	117039
2026-03-25	SRPT	23.74	0.89	0.21	118132
2026-03-26	SRPT	21.67	0.81	0.53	125415
2026-03-27	SRPT	19.95	0.81	0.46	125467
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	SRPT	16.31	115.0	345.9	2.38
2026-03-03	SRPT	15.88	124.6	343.4	2.38
2026-03-04	SRPT	16.08	119.4	344.6	2.38
2026-03-05	SRPT	16.23	119.4	345.4	2.38
2026-03-06	SRPT	16.70	119.4	346.9	2.38
2026-03-09	SRPT	17.64	126.8	767.7	4.33
2026-03-10	SRPT	17.67	126.8	767.8	4.33
2026-03-11	SRPT	17.56	128.8	767.3	4.33
2026-03-12	SRPT	17.06	128.8	764.5	4.33
2026-03-13	SRPT	16.41	128.8	760.8	4.23
2026-03-17	SRPT	16.84	128.8	763.3	4.38
2026-03-18	SRPT	17.17	128.8	765.1	4.38
2026-03-19	SRPT	16.66	128.8	762.2	4.38
2026-03-20	SRPT	16.69	126.7	762.4	4.17
2026-03-23	SRPT	17.70	126.7	768.0	4.17
2026-03-24	SRPT	17.61	126.7	767.6	4.17
2026-03-25	SRPT	23.78	126.7	801.9	4.17
2026-03-26	SRPT	21.66	126.7	790.1	4.17
2026-03-27	SRPT	19.94	126.7	780.5	4.17
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	SRPT	-0.24	-0.58	22.37
2026-03-03	SRPT	-0.24	-0.58	22.37
2026-03-04	SRPT	-0.24	-0.58	22.37
2026-03-05	SRPT	-0.24	-0.58	22.32
2026-03-06	SRPT	-0.24	-0.58	22.32
2026-03-09	SRPT	-0.24	-0.58	22.32
2026-03-10	SRPT	-0.24	-0.58	22.32
2026-03-11	SRPT	-0.24	-0.58	21.36
2026-03-12	SRPT	-0.24	-0.58	21.36
2026-03-13	SRPT	-0.24	-0.58	21.36
2026-03-17	SRPT	-0.37	-0.58	21.36
2026-03-18	SRPT	-0.37	-0.58	21.36
2026-03-19	SRPT	-0.37	-0.58	21.36
2026-03-20	SRPT	-0.37	-0.58	21.36
2026-03-23	SRPT	-0.37	-0.65	21.36
2026-03-24	SRPT	-0.37	-0.65	21.36
2026-03-25	SRPT	-0.37	-0.65	23.02
2026-03-26	SRPT	-0.37	-0.65	23.02
2026-03-27	SRPT	-0.37	-0.65	23.02
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-3.93

Avg. EPS Est. Current Quarter

0.91

Avg. EPS Est. Next Quarter

1.1

Insider Transactions

-0.37

Institutional Transactions

-0.65

Beta

0.26

Average Sales Estimate Current Quarter

475

Average Sales Estimate Next Quarter

436

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.5

Max Drawdown 5-Year %

-92.7

Target Price

22.33

P/E

Forward P/E

PEG

P/S

0.95

P/B

1.84

P/Free Cash Flow

EPS

-8.44

Average EPS Est. Cur. Y

4.17

EPS Next Y. (Est.)

2.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-38.34

Relative Volume

1.55

Return on Equity vs Sector %

-89.9

Return on Equity vs Industry %

-73.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

1.07

EBIT Estimation

780.5

◆ SRPT Healthcare

$19.97

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

10/20

Pullback

2/25

Volume

0/15

Valuation

13/20

TP/AR

1/10

Options

5/10

RSI

56.1

Range 1M

56.5%

🚀

Momentum Growth

Ride accelerating trends

WEAK

Momentum

10/25

Growth

8/30

Estimates

2/20

Inst/Vol

3/15

Options

5/10

EPS Yr

141.6%

EPS NY

-57.9%

52W%

15.9%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +60.7% upside

Quality

6/30

Valuation

16/30

Growth

7/25

Stability

6/10

LT Trend

2/5

Upside

+60.7%

Quality

Sarepta Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 835

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT

Latest News

—

Caricamento notizie per SRPT…

stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today

news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance

stock history SRPT – Sarepta Therapeutics, Inc. invest stock market

stock prices SRPT premarket after hours

ticker SRPT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: SRPT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y